Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy.
Pediatr Hematol Oncol
; 31(5): 442-7, 2014 Aug.
Article
em En
| MEDLINE
| ID: mdl-24088186
ABSTRACT
The role of erythropoiesis-stimulating agents (ESAs) in the management of chemotherapy-induced anemia (CIA) is becoming increasingly recognized in the field of medical oncology, with paucity of data in pediatrics. We evaluated the efficacy and tolerability of a single-dose darbepoetin alfa, a long-acting ESA, given to 35 pediatric acute lymphoblastic leukemia (ALL) children during induction chemotherapy. Compared to a retrospective control group, the studied patients have required significantly less units of packed red blood cells (0.88 units/patient in the studied group versus 2.04 units in controls), with no major side effects. We recommend further prospective double-blinded studies with more tailored dosing regimens in pediatric ALL cases and solid tumors.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Eritropoetina
/
Transfusão de Eritrócitos
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Hematínicos
Limite:
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article